CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2022; 80(04): 399-404
DOI: 10.1590/0004-282X-ANP-2021-0202
Articles

Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes

Possíveis papéis da sestrina2 na esclerose múltipla e suas relações com resultados clínicos
1   University of Health Sciences, Konya City Hospital, Department of Neurology, Konya, Turkey.
,
2   Necmettin Erbakan University, Meram Medical School, Department of Neurology, Konya, Turkey.
,
3   Necmettin Erbakan University, Vocational School of Meram, Konya, Turkey.
,
4   Binali Yildirim University Mengücek Gazi Education and Research Hospital, Erzincan, Department of Neurology, Turkey.
,
2   Necmettin Erbakan University, Meram Medical School, Department of Neurology, Konya, Turkey.
,
2   Necmettin Erbakan University, Meram Medical School, Department of Neurology, Konya, Turkey.
› Author Affiliations

ABSTRACT

Background: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. Objective: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. Methods: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. Results: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. Conclusions: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS.

RESUMO

Antecedentes: Caracterizada por desmielinização, inflamação e dano axonal, a esclerose múltipla (EM) é uma das doenças mais comuns do sistema nervoso central liderada pelo sistema imunológico. Há uma necessidade urgente e óbvia de biomarcadores para o diagnóstico e acompanhamento da EM. Objetivo: Investigar os níveis séricos de sestrina2 (SESN2), uma proteína que responde ao estresse agudo, em pacientes com EM. Métodos: Foram incluídos 85 participantes, 40 pacientes com diagnóstico prévio de EM recorrente-remitente e 45 controles saudáveis. Os parâmetros do SESN2 sérico foram investigados em amostras de sangue coletadas de cada participante nos grupos de paciente e controle. Resultados: os níveis de SESN2 foram significativamente mais baixos em pacientes com EM do que em controles (z: -3,06; p=0,002). Na análise ROC do SESN2, o nível preditivo para MS foi 2,36 ng/mL [sensibilidade, 72,50%; especificidade, 55,56%; p=0,002; área sob a curva (AUC)=0,693]. Para o valor de corte em ambos os grupos, SESN2 foi um preditor independente para MS [Exp (B)=3,977, intervalo de confiança de 95% (95%CI) 1,507-10,494; p=0,013]. Conclusões: A expressão diminuída de SESN2 pode desempenhar um papel na patogênese da EM, e SESN2 poderia ser usado como um biomarcador para EM e como agente imunoterapêutico para o tratamento de EM.

Authors’ contributions:

FOO: developed the study idea, collected the data, participated in the statistical calculations and wrote the manuscript; TA, AUU: collected the data, participated in the statistical calculations and approved the final manuscript; TA, FD: participated in the statistical calculations, was involved in literature search and wrote the manuscript; MA, OST: developed the study idea, made and evaluated Doppler ultrasounds and participated in the statistical calculations; TA, AUU: participated in the statistical calculations, analyzed the data and approved the final manuscript; FOO, TA, AUU,: developed the study idea, analyzed the data and approved the final manuscript.




Publication History

Received: 27 May 2021

Accepted: 29 June 2021

Article published online:
06 February 2023

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil